Cwm LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Cwm LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 770.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,506 shares of the biopharmaceutical company’s stock after purchasing an additional 31,425 shares during the quarter. Cwm LLC’s holdings in Regeneron Pharmaceuticals were worth $18,641,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. E Fund Management Hong Kong Co. Ltd. grew its stake in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 31 shares in the last quarter. Activest Wealth Management lifted its holdings in Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 21 shares during the period. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals during the first quarter worth $27,000. Saudi Central Bank purchased a new stake in Regeneron Pharmaceuticals during the first quarter worth $27,000. Finally, Colonial Trust Advisors bought a new stake in Regeneron Pharmaceuticals during the first quarter valued at about $32,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.9%

Shares of Regeneron Pharmaceuticals stock opened at $564.63 on Monday. The stock has a market cap of $59.85 billion, a P/E ratio of 14.23, a P/E/G ratio of 1.80 and a beta of 0.31. The stock’s 50 day simple moving average is $573.95 and its 200-day simple moving average is $564.02. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,024.36. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion during the quarter, compared to analysts’ expectations of $3.30 billion. During the same period last year, the business earned $11.56 earnings per share. Regeneron Pharmaceuticals’s revenue was up 3.6% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.87%.

Analysts Set New Price Targets

REGN has been the subject of several analyst reports. Jefferies Financial Group increased their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a report on Wednesday, August 27th. BMO Capital Markets increased their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a report on Monday, August 4th. Argus lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 30th. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 target price for the company. in a research report on Friday, August 1st. Finally, Truist Financial lowered their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $817.46.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.